Genmab Acquires ProfoundBio for $1.8 Billion to Expand Cancer Treatment Options

The deal enhances Genmab's portfolio with advanced antibody-drug conjugates, marking a significant move in the pharmaceutical industry's focus on targeted cancer therapies.